EDIT
Editas Medicine IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$299.49M
P/E Ratio
—
EPS
$-1.80
Beta
2.04
52W High
$4.54
52W Low
$1.29
50-Day MA
$2.54
200-Day MA
$2.65
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Editas Medicine Inc
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $40.52M |
| Gross Profit (TTM) | $-49.43M |
| EBITDA | $-94.06M |
| Operating Margin | -56.70% |
| Return on Equity | -198.10% |
| Return on Assets | -23.50% |
| Revenue/Share (TTM) | $0.46 |
| Book Value | $0.28 |
| Price-to-Book | 10.98 |
| Price-to-Sales (TTM) | 7.39 |
| EV/Revenue | 4.219 |
| EV/EBITDA | -1.36 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -19.20% |
| Shares Outstanding | $97.87M |
| Float | $97.51M |
| % Insiders | 0.27% |
| % Institutions | 53.11% |
Historical Volatility
HV 10-Day
85.78%
HV 20-Day
77.71%
HV 30-Day
75.54%
HV 60-Day
92.93%
HV Rank
19.0%
Volatility is currently expanding
Analyst Ratings
Consensus ($5.72 target)
7
Buy5
Hold2
Strong SellData last updated: 4/29/2026